APA (7th ed.) Citation

CC, D., E, W., WC, T., G, S. C., J, C., LE, W., . . . JR, L. (2026). Fludarabine Pharmacokinetic Model-Based Dosing Minimizes the Risk of Graft Rejection in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplantation and cellular therapy, 32(4), 476.e1-476.e14. https://doi.org/10.1016/j.jtct.2025.12.007

Chicago Style (17th ed.) Citation

CC, Dvorak, et al. "Fludarabine Pharmacokinetic Model-Based Dosing Minimizes the Risk of Graft Rejection in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation." Transplantation and Cellular Therapy 32, no. 4 (2026): 476.e1-476.e14. https://doi.org/10.1016/j.jtct.2025.12.007.

MLA (9th ed.) Citation

CC, Dvorak, et al. "Fludarabine Pharmacokinetic Model-Based Dosing Minimizes the Risk of Graft Rejection in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation." Transplantation and Cellular Therapy, vol. 32, no. 4, 2026, pp. 476.e1-476.e14, https://doi.org/10.1016/j.jtct.2025.12.007.